Publication | Closed Access

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus LenvatinibPharmacotherapyLiver CancerCancer TreatmentPharmacologyRadiation OncologyHepatocellular CarcinomaAdvanced Hepatocellular CarcinomaHealth Sciences